KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Tax Provisions (2017 - 2026)

Amneal Pharmaceuticals has reported Tax Provisions over the past 9 years, most recently at $5.7 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 4.41% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $11.3 million, down 40.22%, while the annual FY2025 figure was $11.3 million, 40.22% down from the prior year.
  • Tax Provisions for Q4 2025 was $5.7 million at Amneal Pharmaceuticals, up from -$23.4 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $16.1 million in Q2 2025 and troughed at -$23.4 million in Q3 2025.
  • A 5-year average of $2.8 million and a median of $3.9 million in 2021 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: tumbled 975.0% in 2022 and later surged 15830.43% in 2024.
  • Year by year, Tax Provisions stood at $4.1 million in 2021, then plummeted by 143.44% to -$1.8 million in 2022, then soared by 647.33% to $9.9 million in 2023, then crashed by 44.96% to $5.4 million in 2024, then grew by 4.41% to $5.7 million in 2025.
  • Business Quant data shows Tax Provisions for AMRX at $5.7 million in Q4 2025, -$23.4 million in Q3 2025, and $16.1 million in Q2 2025.